Cargando…
A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma
Anti-angiogenic therapy, targeting vascular endothelial growth factor (VEGF)-A/VEGF receptors (VEGFRs), is beneficial for tumor growth prevention in a malignant glioma. A simultaneous blockade using both bevacizumab (Bev), which targets circulating VEGF-A, and a multi-kinase inhibitor on VEGFRs was...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564945/ https://www.ncbi.nlm.nih.gov/pubmed/32887369 http://dx.doi.org/10.3390/vaccines8030498 |
_version_ | 1783595827755745280 |
---|---|
author | Tamura, Ryota Morimoto, Yukina Sato, Mizuto Hikichi, Tetsuro Yoshida, Kazunari Toda, Masahiro |
author_facet | Tamura, Ryota Morimoto, Yukina Sato, Mizuto Hikichi, Tetsuro Yoshida, Kazunari Toda, Masahiro |
author_sort | Tamura, Ryota |
collection | PubMed |
description | Anti-angiogenic therapy, targeting vascular endothelial growth factor (VEGF)-A/VEGF receptors (VEGFRs), is beneficial for tumor growth prevention in a malignant glioma. A simultaneous blockade using both bevacizumab (Bev), which targets circulating VEGF-A, and a multi-kinase inhibitor on VEGFRs was more effective for advanced solid cancers, including melanoma and renal cell carcinoma. However, previous clinical trials demonstrated a high adverse event rate. Additionally, no studies previously assessed treatment efficacy and safety using both VEGF-A and VEGFR-targeted agents for malignant gliomas. We had conducted clinical trials investigating VEGFRs peptide vaccination in patients with malignant gliomas, in which the treatment exhibited safety and yielded therapeutic effects in some patients. The combined use of Bev and VEGFRs vaccination may enhance the anti-tumor effect in malignant gliomas. In this pilot study, the adverse event profile in patients treated with Bev after the vaccination was investigated to establish this treatment strategy, in comparison to those treated with Bev collected from the published data or treated with the vaccination alone. In our previous clinical studies on patients with malignant gliomas, Bev was administered to 13 patients after VEGFRs vaccinations. One patient had a Grade 4 pulmonary embolism. Two patients had Grade 2 cerebral infarctions. There were no significant differences in the adverse event rates among patients treated with Bev, with the vaccination, or with Bev after the vaccination. Although careful observation is imperative for patients after this combination treatment strategy, VEGFRs-targeted vaccination may coexist with Bev for malignant gliomas. |
format | Online Article Text |
id | pubmed-7564945 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75649452020-10-26 A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma Tamura, Ryota Morimoto, Yukina Sato, Mizuto Hikichi, Tetsuro Yoshida, Kazunari Toda, Masahiro Vaccines (Basel) Communication Anti-angiogenic therapy, targeting vascular endothelial growth factor (VEGF)-A/VEGF receptors (VEGFRs), is beneficial for tumor growth prevention in a malignant glioma. A simultaneous blockade using both bevacizumab (Bev), which targets circulating VEGF-A, and a multi-kinase inhibitor on VEGFRs was more effective for advanced solid cancers, including melanoma and renal cell carcinoma. However, previous clinical trials demonstrated a high adverse event rate. Additionally, no studies previously assessed treatment efficacy and safety using both VEGF-A and VEGFR-targeted agents for malignant gliomas. We had conducted clinical trials investigating VEGFRs peptide vaccination in patients with malignant gliomas, in which the treatment exhibited safety and yielded therapeutic effects in some patients. The combined use of Bev and VEGFRs vaccination may enhance the anti-tumor effect in malignant gliomas. In this pilot study, the adverse event profile in patients treated with Bev after the vaccination was investigated to establish this treatment strategy, in comparison to those treated with Bev collected from the published data or treated with the vaccination alone. In our previous clinical studies on patients with malignant gliomas, Bev was administered to 13 patients after VEGFRs vaccinations. One patient had a Grade 4 pulmonary embolism. Two patients had Grade 2 cerebral infarctions. There were no significant differences in the adverse event rates among patients treated with Bev, with the vaccination, or with Bev after the vaccination. Although careful observation is imperative for patients after this combination treatment strategy, VEGFRs-targeted vaccination may coexist with Bev for malignant gliomas. MDPI 2020-09-02 /pmc/articles/PMC7564945/ /pubmed/32887369 http://dx.doi.org/10.3390/vaccines8030498 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Tamura, Ryota Morimoto, Yukina Sato, Mizuto Hikichi, Tetsuro Yoshida, Kazunari Toda, Masahiro A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma |
title | A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma |
title_full | A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma |
title_fullStr | A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma |
title_full_unstemmed | A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma |
title_short | A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma |
title_sort | pilot study of the adverse events caused by the combined use of bevacizumab and vascular endothelial growth factor receptor-targeted vaccination for patients with a malignant glioma |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564945/ https://www.ncbi.nlm.nih.gov/pubmed/32887369 http://dx.doi.org/10.3390/vaccines8030498 |
work_keys_str_mv | AT tamuraryota apilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma AT morimotoyukina apilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma AT satomizuto apilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma AT hikichitetsuro apilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma AT yoshidakazunari apilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma AT todamasahiro apilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma AT tamuraryota pilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma AT morimotoyukina pilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma AT satomizuto pilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma AT hikichitetsuro pilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma AT yoshidakazunari pilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma AT todamasahiro pilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma |